Sulfate-reducing bacteria respiration approach to fabricating flexible N,S-reduced graphene oxide thin film electrode for in situ cancer biomarker detection
Publication date: Available online 21 January 2020Source: Journal of Electroanalytical ChemistryAuthor(s): Shuang Dong, Zhengyun Wang, Junlei Wang, Muhammad Asif, Yin Yao, Fei Xiao, Hongfang LiuAbstractThe significance of in situ detection of small biomolecules associated with specific cancer diseases have stimulated the design of flexible film electrode materials. In this work, a green and facile strategy was presented to fabricate flexible N,S-reduced graphene oxide film (N,S-rGOF) by respiratory mechanism of sulfate-reducing bacteria (SRB). The used microbial method allows us to fabricate N,S-rGOF under green and mild conditions. Benefiting from simultaneous double doping of N and S atoms into graphene structure, the as-obtained flexible N,S-rGOF demonstrates excellent electrochemical sensing activity towards cancer biomarker hydrogen peroxide (H2O2) detection in terms of high sensitivity, good stability and particular reproducibility. The current response has a linear relationship with the concentration of H2O2 up to 45.5 mM. The detection limit is 50 μM (S/N = 3), and the detection sensitivity is 47 μA cm−2 mM−1. It is worth noting that the direct growth of breast cancer cells on N,S-rGOF can largely shorten the diffusion distance of H2O2 molecules to the active sites on N,S-rGOF surface, and therefore increases the sensitivity and accuracy of in situ detection, which offers new clinical possibilities for breast cancer diagnosis and treatm...
Conclusions: Docetaxel and epirubicin neoadjuvant chemotherapy showed a good response in locally advanced breast cancer. Pretreatment Ki-67 and change of Ki-67 may play a role as predictive factor for response to neoadjuvant chemotherapy. PMID: 32069523 [PubMed - as supplied by publisher]
Condition: Primary Breast Cancer Intervention: Diagnostic Test: SPECT Sponsors: Tomsk National Research Medical Center of the Russian Academy of Sciences; Institute of Bioorganic Chemistry, Russian Academy of Sciences; Uppsala University Enrolling by invitation
Condition: Breast Neoplasms Intervention: Drug: DZD3969 Sponsor: Dizal (Jiangsu) Pharmaceutical Co., Ltd. Not yet recruiting
Condition: Early Hormone Receptor-positive Breast Cancer Intervention: Drug: Chemotherapy Drugs, Cancer Sponsor: Gencurix, Inc. Recruiting
To determine the relationship of ablation margin with overall survival (OS), time to progression (TTP) and local recurrence after percutaneous thermal ablation of liver, lung and bone/soft tissue metastases from oligometastatic breast cancer (BC).
To evaluate safety and efficacy of transarterial hepatic Y90 radioembolization in patients with breast cancer liver metastases.
To determine the relationship of radiation dose to imaging response, survival, and toxicity after radioembolization (RE) of liver metastasis from breast cancer.
To perform a Phase I veterinary clinical trial with a low-cost, carbon-dioxide-based, passive thaw cryoablation device1 as proof-of-principle for application in pets and translation to third-world treatment of breast cancer.
The mobilization of the immune system as a therapeutic strategy has emerged as a transformative approach to the treatment of cancer. Intratumoral injection of plasmid IL-12, tavokinogene telseplasmid (TAVO), and co-localized reversible electroporation has demonstrated safe and promising results in the nearly 200 patients enrolled in trials for melanoma, breast cancer, and SCCHN. This current delivery platform uses an applicator capable of reaching lesions no more than 1.5 cm at or below the skin.
ConclusionsApplying the Kaiser score to breast MRI allows stratifying the risk of breast cancer in lesions that present as suspicious calcifications on mammography and may thus avoid unnecessary breast biopsies.Key Points• The Kaiser score is a helpful clinical decision tool for distinguishing malignant from benign breast lesions that present as calcifications on mammography.• Application of the Kaiser score may obviate 58.3–65.3% of unnecessary stereotactic biopsies of suspicious calcifications.• High Kaiser scores predict breast cancer with high specificity, aiding clinical decision-making with regar...